Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash & Current Investments: 2019-2024

Historic Cash & Current Investments for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to $14.9 million.

  • Eton Pharmaceuticals' Cash & Current Investments rose 83.21% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.9 million, marking a year-over-year increase of 24.81%. This contributed to the annual value of $14.9 million for FY2024, which is 30.17% down from last year.
  • According to the latest figures from FY2024, Eton Pharmaceuticals' Cash & Current Investments is $14.9 million, which was down 30.17% from $21.4 million recorded in FY2023.
  • Eton Pharmaceuticals' 5-year Cash & Current Investments high stood at $21.4 million for FY2023, and its period low was $14.4 million during FY2021.
  • Moreover, its 3-year median value for Cash & Current Investments was $16.3 million (2022), whereas its average is $17.5 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Cash & Current Investments spiked by 76.49% in 2020, and later tumbled by 32.35% in 2021.
  • Eton Pharmaceuticals' Cash & Current Investments (Yearly) stood at $21.3 million in 2020, then crashed by 32.35% to $14.4 million in 2021, then grew by 13.18% to $16.3 million in 2022, then spiked by 31.17% to $21.4 million in 2023, then plummeted by 30.17% to $14.9 million in 2024.